

BB Adamant Global Biotech D Class

Factsheet as of 31 October 2015

> Performance in %

Since	1m	YTD	1yr	3yrs	5yrs	Incept.
Fund net	12.3	2.7	6.6	168.0	245.1	245.0
Benchmark	8.6	6.5	12.6	162.5	268.5	280.0
Difference net	3.8	-3.7	-6.0	5.5	-23.4	-35.0
Annualised			3yrs	5yrs	Incept.	
Fund net			38.9	28.1	27.8	
Benchmark			37.9	29.8	30.3	
Difference net			1.0	-1.7	-2.5	

Minor deviation in net performance can be caused by rounding errors


> Fund Description

The BB Adamant Global Biotech fund invests globally in the biotech sector. The investment focus is on companies which are developing therapies for diseases with unmet medical needs. The fund also invests in diagnostic companies which enable a more targeted research for such diseases or companion diagnostics products for a more targeted treatment. The fund aims to give investors a favourable risk-return exposure within the biotech sector. Therefore the fund concentrates its investments in more mature companies which already have products on the market. Early stage development companies with high potential drug pipelines diversify the portfolio. Most of the investments are therefore currently in the United States. At present, the market for biotech drugs generates sales of over USD 100bn and is growing at an annual rate of approximately 15%.

> Fund Facts

Swiss Sec. No.	11'381'712
ISIN	CH0113817123
Fund Inception Date	15.10.2010
Fund Currency	CHF
Net Asset Value	CHF 3'449.91
Shares Outstanding	in thousands 26.07
Subfund Size Class	million 89.93
Total Fund Size	million 147.07
Last Dividend Pay.	CHF n.a.
52-Week High	CHF 4'161.45
52-Week Low	CHF 2'907.47
TER p.a.	1.22%
Fund Manager	Bellevue Asset Management AG, Zürich
Custodian Bank	Zürcher Kantonalbank
Fund Manag. Company	Swisscanto Fondsleitung AG, Zürich
Benchmark	NASDAQ Biotechnology Index (NBI) CR in CHF
TER p.a. refers to latest published annual- or semi-annual report.	

> Indexed Performance



Since fund inception or at the longest for the last five years

> Investment Strategy

Rising life expectancy and demographic changes in the population structure are leading to a sharp upturn in age-related diseases. Hence there is an increasing demand for better treatment solutions. Major progress in the treatment of cardiovascular diseases means that cancer has now overtaken cardiovascular diseases as the number one cause of death. Neurodegenerative diseases such as Alzheimer's and Parkinson's are also affecting a growing number of patients. Especially in these areas, the early stage biotechnology companies are making tremendous progress.


> Main Investment Principles

Although the biotechnology sector has barely left its infancy, it has already achieved some major treatment successes. The latest statistics from Europe show a decline in mortality rates among cancer patients in recent years thanks to improvements in diagnosis and treatment. Despite this, biotechnology drugs only account for 2% of the global healthcare market. Modern biotechnology is based on the exponential expansion in our knowledge of diseases at the molecular and cellular level, translating into an attractive pipeline offering and potential future treatment successes.


> 10 Largest Positions

Celgene	9.4%
Amgen	9.1%
Gilead	9.0%
Biogen	8.6%
Regeneron	7.6%
Illumina	4.5%
Vertex	4.0%
Incyte	3.7%
Alexion	3.6%
Mylan	3.3%
Total Exposure	115.0%


> Currency Allocation



> Breakdown by Sector



> Allocation by Market Capitalization



> Key Figures

	1 year annualised realised	3 years annualised realised	5 years annualised realised
Tracking Error	6.5%	5.4%	5.5%
Volatility Fund	28.7%	24.6%	22.3%
Volatility Benchmark	24.8%	21.3%	19.6%
Beta	1.1	1.1	1.1
Sharpe Ratio	0.2	1.3	1.1
Jensen's Alpha	-7.1	-3.6	-4.1
Information Ratio	-0.8	0.1	-0.2

The fund has been approved in Switzerland by the supervisory authority, the Swiss Financial Market Authority (FINMA).

Disclaimer

This Publication is for information purposes only and does not explicitly target any person who by domicile or nationality is prohibited to receive such information according to applicable law. Investors are advised that past performance is not an indicator of current or future performance and that the performance data do not take account of commission and expenses charged on the issue and redemption of units. The BB Adamant Funds are investment funds under Swiss law in the "Other funds for traditional investments" category and have been established under the Swiss Collective Investment Schemes Act. The Fund's prospectus respectively key investor information, regulations and annual report may be obtained free of charge from the Fund Manager and the Custodian Bank. This document was produced by Zürcher Kantonalbank ("ZKB") applying highest diligence standards in good faith. ZKB does not warrant any guarantee with regard to correctness and completeness and waives any claim for losses that may occur through the use of this information. This Publication is neither an offer nor a recommendation for the purchase or sale of financial products or financial services and does not discharge the recipient from his own judgement. Particularly, ZKB recommends that the recipient, if need be by consulting professional guidance, assess the information in consideration of his personal situation with regard to legal, regulatory and tax consequences that might be invoked. The present document is not the result of the department "financial analysis" as defined in the rules of the "Directives on the Independence of Financial Research" edited by the Swiss Bankers Association, hence these rules do not apply to this document.

This document is for distribution and / or redistribution only to persons who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Financial Promotion Order"), (ii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc") of the Financial Promotion Order, (iii) are outside the United Kingdom, or (iv) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "relevant persons"). This document is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this document relates is available only to relevant persons and will be engaged in only with relevant persons.

The enclosed document is only made available on the condition that it will be exclusively used by the recipient and must not be forwarded to other persons or reproduced either in part or in full. The units will not be placed as part of an active offer. The intended distribution of the units was therefore not reported to the financial market supervisory authority and the units are not part of a published prospectus in Austria. All enclosed information relating to the units thus neither represents part of a prospectus within the meaning of the Investment Fund Act (InvFG), information within the meaning of § 21 of the Alternative Investment Fund Managers Act (AIFMG) nor a prospectus within the meaning of the Capital Markets Act (KMG).

If Balfidior Fondsleitung AG, Adamant Funds or Zürcher Kantonalbank enter into a business or contractual relationship with a client whose registered office, permanent or temporary residence, domicile, administrative office or management is in Austria, these contractual terms and conditions arise exclusively at the client's own initiative and discretion. Investors are hereby informed that earnings, capital gains and capital gains tax on units are not currently reported by a tax representative to the Swiss Federal Ministry of Finance (BMF) nor to the Austrian OeKB. Accordingly, there may be detrimental taxation consequences. Taxation depends on the personal circumstances of the investor and may change in future.

This publication and the information contained in it must not be distributed and / or redistributed to, used or relied upon by, any person (whether individual or entity) who may be a US person under Regulation S under the US Securities Act of 1933. US persons include any US resident; any corporation, company, partnership or other entity organized under the any law of the United States; and other categories set out in Regulation S.

This document does not constitute an offer to sell or a solicitation or invitation to subscribe for or to make an offer to buy any securities, nor does it provide a basis for any contract or obligation of any kind. This document is not a prospectus within the meaning of article 652a or 1156 the Swiss Code of Obligations or Article 27 of the listing rules of SIX Swiss Exchange AG.

Copyright © 2015 Zürcher Kantonalbank. All rights reserved.